Cutting Through the Noise: for COVID-19 Vaccines & Therapeutics Wednesday, July 22 | 12:30–1:30 PM ET Market Evolution & Pathways to Access Webinar COVID-19 Intel Center Plan for Implications Rely on Our Robust Proprietary Data Federal PolicyMajority of API in US-Consumed Medicines is Produced in the USFederal PolicyProposed Medicaid Line Extension Definition Alters Rebate CalculationState PolicyExchanges May Add More than 1 Million New Enrollees due to COVID-19 Federal PolicyComparison of Dually and Non-Dually Eligible Patients with ESRDCOVID-19 Intel CenterCOVID-19 Guide for Patients and ProvidersCOVID-19 Intel CenterHow COVID-19 Could Reduce MA Risk Scores and Payments in 2021Federal PolicyMedicaid VBP Rule May Facilitate Drug Contracts, But Questions RemainReal-World DataNew Data Approaches for Novel Curative Therapies and APMs“There is increasing investment in RWE generation to assess the value of new therapies.”Allison PetrillaManaging Director0MAmericans experience food insecurityCOVID-19 Intel CenterWebinar: Cutting Through the Noise: Market Evolution and Pathways to Access for COVID-19 Vaccines and Therapeutics “Expanded opportunities exist for new drugs and devices to achieve NTAP status”Abby MoormanSenior Consultant0%Oncology patients receive a biomarker testValue-Based CareAvalere Helps NYSHealth Improve Physician-Patient Cost Conversations
